Scribe Therapeutics Inc.

What they do

Scribe Therapeutics engineers purpose-built in vivo CRISPR technologies intended to extend healthy lifespan through disease prevention and durable therapeutic intervention. Its lead asset, STX-1150, is a liver-targeted epigenetic silencing therapy designed to repress PCSK9 transcription and lower LDL-C without permanently altering DNA. The company is also advancing STX-1200 for Lp(a) lowering and STX-1400 for triglyceride lowering, targeting the three major lipid drivers of atherosclerotic cardiovascular disease.

Revenue drivers

• Grant funding — Scribe was awarded more than $25 million from the California Institute for Regenerative Medicine (CIRM) to advance STX-1200 and STX-1400 toward clinical entry.
• Collaboration or licensing arrangements — The company completed a concurrent private placement to Sanofi in connection with its IPO, though no ongoing collaboration revenue is disclosed in the provided excerpts.
• Pre-clinical and clinical stage operations — Quarterly revenue of $1.9M for the period ended 2026-06-30 is reported, down from $4.9M in the prior-year quarter, but no segment or product-level revenue breakdown is provided in the excerpts.

Recent performance

Second quarter 2026 revenue was $1.9 million, down from $4.9 million in the quarter ended June 30, 2025. Total assets were $57.9 million at June 30, 2026, total liabilities were $102.4 million, and shareholders' equity was negative $164.8 million. Cash and equivalents stood at $35.6 million at quarter end. The company subsequently completed an upsized IPO and concurrent private placement to Sanofi generating approximately $155.5 million in aggregate gross proceeds, with approximately $140.6 million in net proceeds received in July 2026. Management states this funding supports operations into the first half of 2029.

Strategy

Scribe is prioritizing clinical advancement of STX-1150, which entered a first-in-human Phase 1 trial in Australia in mid-2026 for adults with elevated LDL-C and increased ASCVD risk. It is using CIRM grant funding to move STX-1200 and STX-1400 toward clinical entry, targeting Lp(a) and triglycerides. The company aims to shift cardiovascular treatment from chronic symptom management toward durable disease prevention using epigenetic silencing that avoids permanent genetic changes. It completed its IPO and a concurrent private placement to Sanofi to fund these programs into the first half of 2029.

Risks

• Early clinical stage — STX-1150 has only just initiated a Phase 1 trial, and safety, tolerability and efficacy in humans are unproven.
• Going concern and negative equity — At June 30, 2026, total liabilities of $102.4 million exceeded total assets of $57.9 million, and shareholders' equity was negative $164.8 million.
• Revenue decline — Quarterly revenue fell to $1.9 million for the period ended 2026-06-30 from $4.9 million in the prior-year quarter.
• Dependence on external funding — The company relies on grant funding and capital markets, having just raised approximately $155.5 million gross in its IPO and concurrent private placement to fund operations.

Outlook

Management states that cash, cash equivalents, and marketable securities of $43.0 million as of June 30, 2026, plus approximately $140.6 million of net proceeds from the July 2026 IPO and concurrent private placement, provides funding into the first half of 2029. The company expects to continue the Phase 1 trial of STX-1150 and advance STX-1200 and STX-1400 toward clinical entry with CIRM support. Scribe aims to execute across a portfolio targeting LDL-C, Lp(a), and triglycerides.